1 citations
,
December 2018 in “IntechOpen eBooks” Human hair shows promise for non-invasive medical testing, but more research is needed to standardize its use.
Higher cortisol levels might be linked to worsening keratoconus.
January 2026 in “Non-coding RNA Research” Exosomal miRNA-218-5p promotes hair growth and development.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
December 2025 in “Frontiers in Endocrinology” High chromogranin A levels are linked to obesity and inflammation in polycystic ovary syndrome.
December 2025 in “Clinical Cosmetic and Investigational Dermatology” ZDHHC17 methylation may help treat or identify facial skin aging.
November 2025 in “BMC Endocrine Disorders” The TT/DHT ratio may help identify PCOS patients with severe metabolic issues.
November 2025 in “Clinical and Translational Medicine” DNAJB9 cfRNA could help diagnose and treat female hair loss.
October 2025 in “European Journal of Translational and Clinical Medicine” High serum DHT levels can help diagnose PCOS.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
July 2025 in “The Egyptian Journal of Hospital Medicine” Estrogen affects hair growth, and GPER-1 levels might help identify hair loss types.
June 2025 in “Medical Science Journal for Advance Research” Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Oral minoxidil boosts hair growth and reduces shedding in androgenetic alopecia.
January 2025 in “International Journal of Forest Animal and Fisheries Research” DHEA may play a complex role in PCOS, affecting hormones, metabolism, and symptoms.
October 2024 in “Skin Appendage Disorders” Higher FABP4 levels may indicate more severe alopecia areata.
January 2024 in “The Egyptian Journal of Hospital Medicine” Men with male pattern baldness have higher levels of A-FABP, which might help in early detection.
January 2024 in “International Journal of Trichology” PON1 levels might indicate hair loss severity, but other health factors can affect this.
December 2023 in “Benha Journal of Applied Sciences” Men with male pattern baldness have higher blood sugar, bad cholesterol, and ZAG protein levels than healthy men.
April 2023 in “The Egyptian Journal of Hospital Medicine” Higher Interleukin 17A levels may indicate more severe alopecia areata.
January 2023 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Acne patients have higher mTOR gene expression.
December 2021 in “Benha Journal of Applied Sciences” Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
September 2019 in “Journal of Investigative Dermatology” Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.
Hair cortisol content can indicate cortisol exposure and varies with age, puberty, and BMI in youth.
January 2018 in “한국피부장벽학회지” DHCer levels in hair could be a biomarker for alopecia progression.
February 2017 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Hair cortisol measurement is a promising, non-invasive tool for monitoring cortisol exposure over time.
January 2017 in “NASA Technical Reports Server (NASA)” Early changes in skin gene expression can predict later bone mass loss after radiation exposure.
January 2017 in “Elsevier eBooks” Antioxidants may help improve mitochondrial health and could be used to treat diseases related to cell damage.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.